| 摘要 |
The present invention relates to a pharmaceutical composition for treating central nervous system injury-related diseases, wherein a CCL2 or CCL2 agonist is contained as an active ingredient. The CCL2 exhibits an effect in promoting the regeneration of the axon caused by conditioning injury (CI) by mediating an interaction between the neuron and the macrophagocyte, thereby effectively treating central nervous system injury diseases such as cerebral apoplexy and spinal cord injury. A candidate medicine for promoting the expression of activation of CCL2 is selected, thereby screening a medicine for treating central nervous system injury-related diseases. |
